BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31711370)

  • 21. In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
    Bordallo-Cardona MÁ; Escribano P; de la Pedrosa EG; Marcos-Zambrano LJ; Cantón R; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance.
    Dudiuk C; Gamarra S; Leonardeli F; Jimenez-Ortigosa C; Vitale RG; Afeltra J; Perlin DS; Garcia-Effron G
    J Clin Microbiol; 2014 Jul; 52(7):2609-14. PubMed ID: 24829248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
    Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Surveyor nuclease for rapid identification of FKS genes mutations in Candida glabrata.
    Khalifa HO; Arai T; Majima H; Watanabe A; Kamei K
    J Infect Chemother; 2021 Jun; 27(6):834-839. PubMed ID: 33582033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: Fifteen years of interpretation and assessment.
    Fraser M; Borman AM; Thorn R; Lawrance LM
    Med Mycol; 2020 Feb; 58(2):219-226. PubMed ID: 31111912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study.
    Biswas C; Chen SC; Halliday C; Kennedy K; Playford EG; Marriott DJ; Slavin MA; Sorrell TC; Sintchenko V
    Clin Microbiol Infect; 2017 Sep; 23(9):676.e7-676.e10. PubMed ID: 28344162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
    Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3528-35. PubMed ID: 23669387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.
    Klotz U; Schmidt D; Willinger B; Steinmann E; Buer J; Rath PM; Steinmann J
    Mycoses; 2016 May; 59(5):312-8. PubMed ID: 26806376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.
    Costa-de-Oliveira S; Marcos Miranda I; Silva RM; Pinto E Silva A; Rocha R; Amorim A; Gonçalves Rodrigues A; Pina-Vaz C
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1312-4. PubMed ID: 21149621
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Suwunnakorn S; Wakabayashi H; Kordalewska M; Perlin DS; Rustchenko E
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358288
    [No Abstract]   [Full Text] [Related]  

  • 31. Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata.
    Pham CD; Bolden CB; Kuykendall RJ; Lockhart SR
    J Clin Microbiol; 2014 Mar; 52(3):790-5. PubMed ID: 24353003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of caspofungin susceptibility of Candida glabrata by the Etest®, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations.
    Bourgeois N; Laurens C; Bertout S; Balard Y; Krasteva D; Rispail P; Lachaud L
    Eur J Clin Microbiol Infect Dis; 2014 Jul; 33(7):1247-52. PubMed ID: 24522619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility.
    Healey KR; Katiyar SK; Castanheira M; Pfaller MA; Edlind TD
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3947-9. PubMed ID: 21628537
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Jiménez-Ortigosa C; Perez WB; Angulo D; Borroto-Esoda K; Perlin DS
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.
    Niimi K; Monk BC; Hirai A; Hatakenaka K; Umeyama T; Lamping E; Maki K; Tanabe K; Kamimura T; Ikeda F; Uehara Y; Kano R; Hasegawa A; Cannon RD; Niimi M
    J Antimicrob Chemother; 2010 May; 65(5):842-52. PubMed ID: 20233776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
    Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
    Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
    Thompson GR; Wiederhold NP; Vallor AC; Villareal NC; Lewis JS; Patterson TF
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3783-5. PubMed ID: 18676885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Echinocandin-Resistant
    Bordallo-Cardona MÁ; Sánchez-Carrillo C; Bouza E; Muñoz P; Escribano P; Guinea J
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.